Weighted Average Number of Shares Outstanding, Diluted of GUIDED THERAPEUTICS INC from 31 Mar 2015 to 30 Sep 2025

Taxonomy & unit
us-gaap: shares
Description
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
Summary
GUIDED THERAPEUTICS INC quarterly and annual Weighted Average Number of Shares Outstanding, Diluted in shares history and change rate from 31 Mar 2015 to 30 Sep 2025.
  • GUIDED THERAPEUTICS INC Weighted Average Number of Shares Outstanding, Diluted for the quarter ending 30 Sep 2025 was 81,689,000.
  • GUIDED THERAPEUTICS INC annual Weighted Average Number of Shares Outstanding, Diluted for 2024 was 57,339.
  • GUIDED THERAPEUTICS INC annual Weighted Average Number of Shares Outstanding, Diluted for 2023 was 51,131,000.
  • GUIDED THERAPEUTICS INC annual Weighted Average Number of Shares Outstanding, Diluted for 2022 was 32,505,000, a 143% increase from 2021.
Source SEC data
View on sec.gov
Weighted Average Number of Shares Outstanding, Diluted, Quarterly (shares)
Weighted Average Number of Shares Outstanding, Diluted, YoY Quarterly Change (%)
Weighted Average Number of Shares Outstanding, Diluted, Annual (shares)
Weighted Average Number of Shares Outstanding, Diluted, YoY Annual Change (%)

GUIDED THERAPEUTICS INC Quarterly Weighted Average Number of Shares Outstanding, Diluted (shares)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 81,689,000* +81,631,961 01 Jul 2025 30 Sep 2025 10-Q 13 Nov 2025 2025 Q3
Q2 2025 78,838,000* +78,782,014 01 Apr 2025 30 Jun 2025 10-Q 14 Aug 2025 2025 Q2
Q1 2025 68,291 +13,541 +25% 01 Jan 2025 31 Mar 2025 10-Q 15 May 2025 2025 Q1
Q4 2024 57,339 01 Oct 2024 31 Dec 2024 10-K 31 Mar 2025 2024 FY
Q3 2024 57,039 -51,415,961 01 Jul 2024 30 Sep 2024 10-Q 13 Nov 2025 2025 Q3
Q2 2024 55,986 -50,914,014 01 Apr 2024 30 Jun 2024 10-Q 14 Aug 2025 2025 Q2
Q1 2024 54,750 +5,453 +11% 01 Jan 2024 31 Mar 2024 10-Q 15 May 2025 2025 Q1
Q3 2023 51,473,000* +16,644,000 01 Jul 2023 30 Sep 2023 10-Q 14 Nov 2024 2024 Q3
Q2 2023 50,970,000* +24,633,000 01 Apr 2023 30 Jun 2023 10-Q 14 Aug 2024 2024 Q2
Q1 2023 49,297 -20,633,703 -100% 01 Jan 2023 31 Mar 2023 10-Q 14 May 2024 2024 Q1
Q4 2022 32,505,000 01 Oct 2022 31 Dec 2022 10-K 28 Mar 2024 2023 FY
Q3 2022 34,829,000* 01 Jul 2022 30 Sep 2022 10-Q 13 Nov 2023 2023 Q3
Q2 2022 26,337,000 +13,057,000 +98% 01 Apr 2022 30 Jun 2022 10-Q 10 Aug 2023 2023 Q2
Q1 2022 20,683,000 +7,511,000 +57% 01 Jan 2022 31 Mar 2022 10-Q 15 May 2023 2023 Q1
Q2 2021 13,280,000 +13,268,087 +111375% 01 Apr 2021 30 Jun 2021 10-Q 15 Aug 2022 2022 Q2
Q1 2021 13,172,000 +13,106,380 +19973% 01 Jan 2021 31 Mar 2021 10-Q 16 May 2022 2022 Q1
Q4 2020 10,767 +7,465 +226% 01 Oct 2020 31 Dec 2020 10-K 07 Apr 2021 2020 FY
Q3 2020 60,331 +57,012 +1718% 01 Jul 2020 30 Sep 2020 10-Q/A 05 Nov 2020 2020 Q3
Q2 2020 11,913 +8,629 +263% 01 Apr 2020 30 Jun 2020 10-Q 20 Aug 2020 2020 Q2
Q1 2020 65,620 +62,372 +1920% 01 Jan 2020 31 Mar 2020 10-Q/A 18 Aug 2021 2021 Q1
Q4 2019 3,302 -61,925 -95% 01 Oct 2019 31 Dec 2019 10-K 07 Apr 2021 2020 FY
Q3 2019 3,319 +2,925 +742% 01 Jul 2019 30 Sep 2019 10-Q/A 05 Nov 2020 2020 Q3
Q2 2019 3,284 +568 +21% 01 Apr 2019 30 Jun 2019 10-Q 20 Aug 2020 2020 Q2
Q1 2019 3,248 +755 +30% 01 Jan 2019 31 Mar 2019 10-Q 07 Jul 2020 2020 Q1
Q4 2018 65,227 +65,227 01 Oct 2018 31 Dec 2018 10-K 20 Apr 2020 2019 FY
Q3 2018 394 -6,490 -94% 01 Jul 2018 30 Sep 2018 10-Q 09 Mar 2020 2019 Q3
Q2 2018 2,716 +800 +42% 01 Apr 2018 30 Jun 2018 10-Q 11 Feb 2020 2019 Q2
Q1 2018 2,493 +1,547 +164% 01 Jan 2018 31 Mar 2018 10-Q 11 Jul 2019 2019 Q1
Q4 2017 0 01 Oct 2017 31 Dec 2017 10-K 08 May 2019 2018 FY
Q3 2017 6,884 +6,601 +2333% 01 Jul 2017 30 Sep 2017 10-Q 14 Nov 2018 2018 Q3
Q2 2017 1,916 +1,875 01 Apr 2017 30 Jun 2017 10-Q 14 Aug 2018 2018 Q2
Q1 2017 946 -108,953 -99% 01 Jan 2017 31 Mar 2017 10-Q 21 May 2018 2018 Q1
Q3 2016 283 +281 01 Jul 2016 30 Sep 2016 10-Q 20 Nov 2017 2017 Q3
Q2 2016 41* -107,215 01 Apr 2016 30 Jun 2016 10-Q 18 Aug 2017 2017 Q2
Q1 2016 109,899 +108,926 +11195% 01 Jan 2016 31 Mar 2016 10-Q 19 May 2016 2016 Q1
Q3 2015 2* 01 Jul 2015 30 Sep 2015 10-Q 05 Dec 2016 2016 Q3
Q2 2015 107,256 01 Apr 2015 30 Jun 2015 10-Q 17 Aug 2016 2016 Q2
Q1 2015 973 01 Jan 2015 31 Mar 2015 10-Q 19 May 2016 2016 Q1

GUIDED THERAPEUTICS INC Annual Weighted Average Number of Shares Outstanding, Diluted (shares)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 57,339 -51,073,661 01 Jan 2024 31 Dec 2024 10-K 31 Mar 2025 2024 FY
2023 51,131,000* +18,626,000 01 Jan 2023 31 Dec 2023 10-K 31 Mar 2025 2024 FY
2022 32,505,000 +19,128,000 +143% 01 Jan 2022 31 Dec 2022 10-K 28 Mar 2024 2023 FY
2021 13,377,000 +13,366,233 +124141% 01 Jan 2021 31 Dec 2021 10-K 30 Mar 2023 2022 FY
2020 10,767 +7,465 +226% 01 Jan 2020 31 Dec 2020 10-K 07 Apr 2021 2020 FY
2019 3,302 -61,925 -95% 01 Jan 2019 31 Dec 2019 10-K 07 Apr 2021 2020 FY
2018 65,227 +65,227 01 Jan 2018 31 Dec 2018 10-K 20 Apr 2020 2019 FY
2017 0 01 Jan 2017 31 Dec 2017 10-K 08 May 2019 2018 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.